Pharmacology, Signaling and Physiological Relevance of the G Protein-coupled Receptor 55

Advances in Pharmacology

Volumn 62, Issue , 2011, Pages 251-277

  Balenga, Nariman A B ^a,c   Henstridge, Christopher M ^b   Kargl, Julia ^a   Waldhoer, Maria ^a,d  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c HAGEDORN RESEARCH INSTITUTE   (Denmark)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Cancer; Cannabinoid; CNS; GPR55; Inflammation; LPI

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; BETA GALACTOSIDASE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FORMYLMETHIONYLLEUCYLPHENYLALANINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 8; LYSOPHOSPHATIDIC ACID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELOPEROXIDASE; PALMIDROL; PROTEIN ABN CBD; PROTEIN C FOS; REACTIVE OXYGEN METABOLITE; RIMONABANT; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

BOOK; BREAST CANCER; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CENTRAL NERVOUS SYSTEM; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIGAND BINDING; NONHUMAN; OVARY CANCER; PHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VASCULARIZATION;

EID: 80052661509     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385952-5.00004-X     Document Type: Chapter

References (105)

1. Adams M.D., Earnhardt J.T., Martin B.R., Harris L.S., Dewey W.L., Razdan R.K. A cannabinoid with cardiovascular activity but no overt behavioral effects. Experientia 1977, 33:1204-1205.
2. Alessi D.R., Cohen P. Mechanism of activation and function of protein kinase B. Current Opinion in Genetics & Development 1998, 8:55-62.
3. Andradas C., Caffarel M.M., Perez-Gomez E., Salazar M., Lorente M., Velasco G., et al. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 2011, 30:245-252.
4. Baker D., Pryce G., Davies W.L., Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends in Pharmacological Sciences 2006, 27:1-4.
5. Balenga N.A.B., Aflaki E., Kargl J., Platzer W., Schröder R., Blättermann S., et al. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Research 2011, (In press).
6. Baltrusch S., Lenzen S. Regulation of [Ca2+]i oscillations in mouse pancreatic islets by adrenergic agonists. Biochemical and Biophysical Research Communications 2007, 363:1038-1043.
7. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., et al. Evidence for novel cannabinoid receptors. Pharmacology & Therapeutics 2005, 106:133-145.
8. Berghuis P., Rajnicek A.M., Morozov Y.M., Ross R.A., Mulder J., Urban G.M., et al. Hardwiring the brain: Endocannabinoids shape neuronal connectivity. Science 2007, 316:1212-1216.
9. Bifulco M., Di M.V. Targeting the endocannabinoid system in cancer therapy: A call for further research. Nature Medicine 2002, 8:547-550.
10. Bondarenko A., Waldeck-Weiermair M., Naghdi S., Poteser M., Malli R., Graier W.F. GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells. British Journal of Pharmacology 2010, 161:308-320.
11. Breivogel C.S., Griffin G., Di M.V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology 2001, 60:155-163.
12. Brown A.J. Novel cannabinoid receptors. British Journal of Pharmacology 2007, 152:567-575.
13. Brown A.J., Daniels D.A., Kassim M., Brown S., Haslam C.P., Terrell V.R., et al. Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. The Journal of Pharmacology and Experimental Therapeutics 2011, 337:236-246.
14. Brown A.J., Robin H.C. Is GPR55 an anandamide receptor?. Vitamins and Hormones 2009, 81:111-137.
15. Brown A.J., Wise A. Identification of modulators of GPR55 activity 2001, GlaxoSmithKline, [WO00186305].
16. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394:277-281.
17. Cinar R., Freund T.F., Katona I., Mackie K., Szucs M. Reciprocal inhibition of G-protein signaling is induced by CB(1) cannabinoid and GABA(B) receptor interactions in rat hippocampal membranes. Neurochemistry International 2008, 52:1402-1409.
18. Davies M.A., Koul D., Dhesi H., Berman R., McDonnell T.J., McConkey D., et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Research 1999, 59:2551-2556.
19. Deutsch D.G., Goligorsky M.S., Schmid P.C., Krebsbach R.J., Schmid H.H., Das S.K., et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. The Journal of Clinical Investigation 1997, 100:1538-1546.
20. Dorsam R.T., Gutkind J.S. G-protein-coupled receptors and cancer. Nature Reviews. Cancer 2007, 7:79-94.
21. Drmota T., Greasley P.J., Groblewski T. Screening assays for cannabinoid-ligand type modulators 2004, AstraZeneca, [WO2004074844].
22. Falasca M., Corda D. Elevated levels and mitogenic activity of lysophosphatidylinositol in k-ras-transformed epithelial cells. European Journal of Biochemistry 1994, 221:383-389.
23. Falasca M., Iurisci C., Carvelli A., Sacchetti A., Corda D. Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferation. Oncogene 1998, 16:2357-2365.
24. Ford L.A., Roelofs A.J., Anavi-Goffer S., Mowat L., Simpson D.G., Irving A.J., et al. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. British Journal of Pharmacology 2010, 160:762-771.
25. Franklin A., Parmentier-Batteur W., Walter L., Greenberg D.A., Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. The Journal of Neuroscience 2003, 23:7767-7775.
26. Fredriksson R., Lagerstrom M.C., Lundin L.G., Schioth H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Molecular Pharmacology 2003, 63:1256-1272.
27. Galve-Roperh I., Sanchez C., Cortes M.L., Gómez d.P., Izquierdo M., Guzman M. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine 2000, 6:313-319.
28. Godlewski G., Offertaler L., Wagner J.A., Kunos G. Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins & Other Lipid Mediators 2009, 89:105-111.
29. Guzman M. Cannabinoids: Potential anticancer agents. Nature Reviews. Cancer 2003, 3:745-755.
30. Hajos N., Freund T.F. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 2002, 43:503-510.
31. Hajos N., Ledent C., Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001, 106:1-4.
32. Hall W., Solowij N. Adverse effects of cannabis. The Lancet 1998, 352:1611-1616.
33. Haller J., Varga B., Ledent C., Freund T.F. CB1 cannabinoid receptors mediate anxiolytic effects: Convergent genetic and pharmacological evidence with CB1-specific agents. Behavioural Pharmacology 2004, 15:299-304.
34. Harkany T., Mackie K., Doherty P. Wiring and firing neuronal networks: Endocannabinoids take center stage. Current Opinion in Neurobiology 2008, 18:338-345.
35. Henstridge C.M., Balenga N.A., Ford L.A., Ross R.A., Waldhoer M., Irving A.J. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. The FASEB Journal 2009, 23:183-193.
36. Henstridge C.M., Balenga N.A., Schroder R., Kargl J.K., Platzer W., Martini L., et al. GPR55 ligands promote receptor coupling to multiple signalling pathways. British Journal of Pharmacology 2010, 160:604-614.
37. Hillard C.J., Jarrahian A. Cellular accumulation of anandamide: Consensus and controversy. British Journal of Pharmacology 2003, 140:802-808.
38. Ho W.S., Hiley C.R. Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. British Journal of Pharmacology 2003, 138:1320-1332.
39. Jaggar S.I., Hasnie F.S., Sellaturay S., Rice A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998, 76:189-199.
40. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:14136-14141.
41. Johns D.G., Behm D.J., Walker D.J., Ao Z., Shapland E.M., Daniels D.A., et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. British Journal of Pharmacology 2007, 152:825-831.
42. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target?. Nature Reviews. Drug Discovery 2008, 7:961-962.
43. Joseph J., Niggemann B., Zaenker K.S., Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunology, Immunotherapy 2004, 53:723-728.
44. Kapur A., Zhao P., Sharir H., Bai Y., Caron M.G., Barak L.S., et al. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. The Journal of Biological Chemistry 2009, 284:29817-29827.
45. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nature Medicine 2008, 14:923-930.
46. Kenakin T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacological Reviews 1996, 48:413-463.
47. Kurihara R., Tohyama Y., Matsusaka S., Naruse H., Kinoshita E., Tsujioka T., et al. Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. The Journal of Biological Chemistry 2006, 281:12908-12918.
48. Lauckner J.E., Jensen J.B., Chen H.Y., Lu H.C., Hille B., Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:2699-2704.
49. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999, 283:401-404.
50. Lutz S., Shankaranarayanan A., Coco C., Ridilla M., Nance M.R., Vettel C., et al. Structure of Galphaq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs. Science 2007, 318:1923-1927.
51. Mackie K. Cannabinoid receptor homo- and heterodimerization. Life Sciences 2005, 77:1667-1673.
52. Mackie K., Stella N. Cannabinoid receptors and endocannabinoids: Evidence for new players. The AAPS Journal 2006, 8:E298-E306.
53. Matias I., Di M.V. Endocannabinoids and the control of energy balance. Trends in Endocrinology and Metabolism 2007, 18:27-37.
54. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
55. McHugh D., Tanner C., Mechoulam R., Pertwee R.G., Ross R.A. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: Evidence for a site distinct from CB1 and CB2. Molecular Pharmacology 2008, 73:441-450.
56. Mechoulam R., Gaoni Y. Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 1965, 21:1223-1229.
57. Miller A.M., Stella N. CB2 receptor-mediated migration of immune cells: It can go either way. British Journal of Pharmacology 2008, 153:299-308.
58. Milman G., Maor Y., bu-Lafi S., Horowitz M., Gallily R., Batkai S., et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:2428-2433.
59. Mimeault M., Pommery N., Wattez N., Bailly C., Henichart J.P. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down-regulation and ceramide production. The Prostate 2003, 56:1-12.
60. Moriconi A., Cerbara I., Maccarrone M., Topai A. GPR55: Current knowledge and future perspectives of a purported " Type-3" cannabinoid receptor. Current Medicinal Chemistry 2010, 17:1411-1429.
61. Munro S., Thomas K.L., bu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
62. Navarrete M., Araque A. Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 2010, 68:113-126.
63. Nevalainen T., Irving A.J. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?. Current Topics in Medicinal Chemistry 2010, 10:799-813.
64. Nithipatikom K., Endsley M.P., Isbell M.A., Falck J.R., Iwamoto Y., Hillard C.J., et al. 2-Arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Research 2004, 64:8826-8830.
65. Niu J., Profirovic J., Pan H., Vaiskunaite R., Voyno-Yasenetskaya T. G Protein betagamma subunits stimulate p114RhoGEF, a guanine nucleotide exchange factor for RhoA and Rac1: Regulation of cell shape and reactive oxygen species production. Circulation Research 2003, 93:848-856.
66. O'Sullivan S.E., Kendall D.A., Randall M.D. The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. British Journal of Pharmacology 2005, 145:514-526.
67. Ofek O., Karsak M., Leclerc N., Fogel M., Frenkel B., Wright K., et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:696-701.
68. Offertaler L., Mo F.M., Batkai S., Liu J., Begg M., Razdan R.K., et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Molecular Pharmacology 2003, 63:699-705.
69. Oka S., Ikeda S., Kishimoto S., Gokoh M., Yanagimoto S., Waku K., et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. Journal of Leukocyte Biology 2004, 76:1002-1009.
70. Oka S., Kimura S., Toshida T., Ota R., Yamashita A., Sugiura T. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. Journal of Biochemistry 2010, 147:671-678.
71. Oka S., Nakajima K., Yamashita A., Kishimoto S., Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochemical and Biophysical Research Communications 2007, 362:928-934.
72. Oka S., Toshida T., Maruyama K., Nakajima K., Yamashita A., Sugiura T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. The Journal of Biochemistry 2009, 145:13-20.
73. Osei-Hyiaman D., Depetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. The Journal of Clinical Investigation 2005, 115:1298-1305.
74. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics 1997, 74:129-180.
75. Pertwee R.G. Cannabinoid pharmacology: The first 66years. British Journal of Pharmacology 2006, 147(Suppl. 1):S163-S171.
76. Pertwee R.G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Current Medicinal Chemistry 2010, 17:1360-1381.
77. Pietr M., Kozela E., Levy R., Rimmerman N., Lin Y.H., Stella N., et al. Differential changes in GPR55 during microglial cell activation. FEBS Letters 2009, 583:2071-2076.
78. Pineiro R., Maffucci T., Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 2011, 30:142-152.
79. Pistis M., Perra S., Pillolla G., Melis M., Gessa G.L., Muntoni A.L. Cannabinoids modulate neuronal firing in the rat basolateral amygdala: Evidence for CB1- and non-CB1-mediated actions. Neuropharmacology 2004, 46:115-125.
80. Ross R.A. The enigmatic pharmacology of GPR55. Trends in Pharmacological Sciences 2009, 30:156-163.
81. Rouach N., Nicoll R.A. Endocannabinoids contribute to short-term but not long-term mGluR-induced depression in the hippocampus. The European Journal of Neuroscience 2003, 18:1017-1020.
82. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology 2007, 152:1092-1101.
83. Sawzdargo M., Nguyen T., Lee D.K., Lynch K.R., Cheng R., Heng H.H., et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Research. Molecular Brain Research 1999, 64:193-198.
84. Schroder R., Janssen N., Schmidt J., Kebig A., Merten N., Hennen S., et al. Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nature Biotechnology 2010, 28:943-949.
85. Sharir H., Abood M.E. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacology & Therapeutics 2010, 126:301-313.
86. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). British Journal of Pharmacology 2000, 129:227-230.
87. Soria B., Martin F. Cytosolic calcium oscillations and insulin release in pancreatic islets of Langerhans. Diabetes & Metabolism 1998, 24:37-40.
88. Stables J., Mattheakis L.C., Chang R., Rees S. Recombinant aequorin as reporter of changes in intracellular calcium in mammalian cells. Methods in Enzymology 2000, 327:456-471.
89. Staton P.C., Hatcher J.P., Walker D.J., Morrison A.D., Shapland E.M., Hughes J.P., et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008, 139:225-236.
90. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58:1017-1030.
91. Sutphen R., Xu Y., Wilbanks G.D., Fiorica J., Grendys E.C., LaPolla J.P., et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention 2004, 13:1185-1191.
92. Takabe K., Paugh S.W., Milstien S., Spiegel S. "Inside-Out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacological Reviews 2008, 60:181-195.
93. Van K.A., Wong K., Knight Z.A., Govaerts C., Hahn K.M., Shokat K.M., et al. To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. The Journal of Cell Biology 2006, 174:437-445.
94. Wagner J.A., Varga K., Jarai Z., Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 1999, 33:429-434.
95. Waldeck-Weiermair M., Zoratti C., Osibow K., Balenga N., Goessnitzer E., Waldhoer M., et al. Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. Journal of Cell Science 2008, 121:1704-1717.
96. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. The Journal of Neuroscience 2003, 23:1398-1405.
97. Watson S.J., Benson J.A., Joy J.E. Marijuana and medicine: Assessing the science base: A summary of the 1999 Institute of Medicine report. Archives of General Psychiatry 2000, 57:547-552.
98. White R., Hiley C.R. The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. British Journal of Pharmacology 1998, 125:533-541.
99. Whyte L.S., Ryberg E., Sims N.A., Ridge S.A., Mackie K., Greasley P.J., et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:16511-16516.
100. Wu C.S., Zhu J., Wager-Miller J., Wang S., O'Leary D., Monory K., et al. Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. The European Journal of Neuroscience 2010, 32:693-706.
101. Xiao Y., Chen Y., Kennedy A.W., Belinson J., Xu Y. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Annals of the New York Academy of Sciences 2000, 905:242-259.
102. Xu Y., Xiao Y., Zhu K., Baudhuin L.M., Lu J., Hong G., et al. Unfolding the pathophysiological roles of bioactive phospholipids. Current Drug Targets. Immune, Endocrine & Metabolic Disorders 2003, 3:23-32.
103. Yin H., Chu A., Li W., Wang B., Shelton F., Otero F., et al. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. The Journal of Biological Chemistry 2009, 284:12328-12338.
104. Zhang X., Maor Y., Wang J.F., Kunos G., Groopman J.E. Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. British Journal of Pharmacology 2010, 160:1583-1594.
105. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:5780-5785.